We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $82.15, marking a +0.72% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.62%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Heading into today, shares of the company had gained 1.52% over the past month, lagging the Medical sector's gain of 2.92% and outpacing the S&P 500's gain of 0.87% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.74, down 16% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 million, up 1356.22% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5 per share and revenue of $905.71 million, which would represent changes of +194.52% and +125869.62%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, CRISPR Therapeutics AG currently has a Forward P/E ratio of 16.44. Its industry sports an average Forward P/E of 23.51, so we one might conclude that CRISPR Therapeutics AG is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, CRISPR Therapeutics AG (CRSP - Free Report) closed at $82.15, marking a +0.72% move from the previous day. The stock outpaced the S&P 500's daily gain of 0.62%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Heading into today, shares of the company had gained 1.52% over the past month, lagging the Medical sector's gain of 2.92% and outpacing the S&P 500's gain of 0.87% in that time.
Investors will be hoping for strength from CRISPR Therapeutics AG as it approaches its next earnings release. The company is expected to report EPS of -$1.74, down 16% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $5.39 million, up 1356.22% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5 per share and revenue of $905.71 million, which would represent changes of +194.52% and +125869.62%, respectively, from the prior year.
Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% higher. CRISPR Therapeutics AG is holding a Zacks Rank of #3 (Hold) right now.
Digging into valuation, CRISPR Therapeutics AG currently has a Forward P/E ratio of 16.44. Its industry sports an average Forward P/E of 23.51, so we one might conclude that CRISPR Therapeutics AG is trading at a discount comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 161, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CRSP in the coming trading sessions, be sure to utilize Zacks.com.